跳至主要内容
临床试验/NCT07269704
NCT07269704已完成1 期

Effect of Nutritional Supplement Alpha-ketoglutarate for Age-related Ocular Disease: An Open Label, Single Arm Study to Evaluate the Effect of Alpha-ketoglutarate Administered Orally in Patients With Age-related Ocular Diseases (Metabolic Eye Therapy)

Stanford University1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2023年8月15日最近更新:
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
17
试验地点
1
主要终点
Mean change in aqueous humor aKG concentration

研究概览

简要总结

The aims of the study are as follows:

  1. Determine how the eye absorbs supplements taken orally.
  2. Look for specific signs in the proteins and substances in the eyes of people with eye diseases who are also taking nutritional supplements.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Able and willing to give written informed consent
  • Able to attend all study visits and complete the study procedures
  • Women of child-bearing potential must have a negative pregnancy test within 2 weeks before cataract surgery. A pregnancy test is not required for postmenopausal women (defined as being at least 12 consecutive months without menses) or those surgically sterilized (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy).

排除标准

  • Diabetes and/or thyroid, liver, kidney, bowel, and metabolic diseases or disorders
  • History of supplement allergy or planned major surgery
  • Received any other clinical trial drug within 4 months
  • Calculated creatinine clearance of less than 30 ml/min

研究组 & 干预措施

Calcium alpha-ketoglutarate (Ca-aKG)

Experimental

At the first and second cataract surgery of the participant, a small amount of tissue (eye fluid ~0.1 ml or 1-2 drops) is removed for analysis. Beginning one week (7 days) prior to their second cataract extraction surgery, the patient takes an oral nutritional supplement (calcium alpha-ketoglutarate) 2 times a day.

干预措施: Calcium alpha-ketoglutarate (Drug)

结局指标

主要结局

Mean change in aqueous humor aKG concentration

时间窗: Baseline and post-supplementation, approximately 28 days

To evaluate the mean difference in fold-change in aKG levels from baseline to post-supplementation in eye fluid

次要结局

  • Mean fold-change in metabolic and retinal pathways(Baseline and post-supplementation, approximately 28 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Vinit Mahajan

Professor of Ophthalmology

Stanford University

研究点 (1)

Loading locations...

相似试验